Precision Medicine News and Research

RSS

Patient's gene profile influences effects of statins

The Montreal Heart Institute Research Centre is once again pushing the limits of knowledge in personalized medicine. A meta-analysis combining the results of several pharmacogenomic studies and involving over 40,000 research subjects now makes it possible to demonstrate a different response to statins according to the patient's gene profile.

29 Oct 2014

InSilico Medicine, CCARL collaborate to improve personalized medicine projects in multiple sclerosis

InSilico Medicine, the company focused on drug discovery for cancer and age-related diseases, announced its investment in a research collaboration with Canada Cancer and Aging Research Laboratories, Inc. The companies will collaborate on improving decision making in clinical oncology and discovery, and personalized medicine projects in multiple sclerosis (MS).

27 Oct 2014

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia.

17 Oct 2014

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer.

16 Oct 2014

University of Pittsburgh awarded NIH grant to lead Big Data to Knowledge Center of Excellence

The National Institutes of Health has awarded the University of Pittsburgh an $11 million, four-year grant to lead a Big Data to Knowledge Center of Excellence, an initiative that will help scientists capitalize more fully on large amounts of available data and to make data science a more prominent component of biomedical research.

10 Oct 2014

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile.

8 Oct 2014

MyCartis announces launch of digital multiplex biomarker analysis platform

MyCartis today announced the launch of Evalution, a multiplex biomarker analysis platform for the life sciences research market.

7 Oct 2014

U-M scientists launch $11.5 million effort to better understand cause of Parkinson's disease

Deep in the brains of the million Americans with Parkinson's disease, changes to their brain cells put them at high risk of dangerous falls -- a problem that resists even the most modern treatments.

7 Oct 2014

CNIO researchers discover new specific marker for cancer stem cells

Tumours are mosaics of cells that are morphologically and molecularly very different. In this cellular heterogeneity, it is calculated that only 1-2% of the tumour mass is made up of cancer stem cells, which over the past years have been suggested to be responsible for the origin of cancer and for the resistance to conventional chemical therapies.

30 Sep 2014

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Luminex Corporation today announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae.

From Luminex 30 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Early detection of cancers on the horizon with supersensitive nanodevice

Extremely early detection of cancers and other diseases is on the horizon with a supersensitive nanodevice being developed at The University of Alabama in Huntsville in collaboration with The Joint School of Nanoscience and Nanoengineering in Greensboro, NC.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

Cedars-Sinai to participate in a consortium studying motor neuron disorders

Investigators at the Cedars-Sinai Board of Governors Regenerative Medicine Institute have received a grant from the National Institutes of Health to participate in a consortium taking the study of motor neuron disorders - such as Lou Gehrig's disease and spinal muscular atrophy - to a new, comprehensive perspective.

26 Sep 2014

Eutropics inks NCI contract to develop Praedicare Dx platform technology for AML treatments

EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management.

24 Sep 2014

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.

24 Sep 2014

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research and the Catalan Institute of Oncology was established with the aim of bringing the company the latest scientific developments to the service combating cancer with two main branches: the development of new drugs and advance the implementation of personalized cancer treatments.

24 Sep 2014

High-throughput ChIP analysis platform introduced in new technical article

Porvair Sciences, in conjunction with researchers at Swansea University (UK) have written a new technical article entitled 'Chromatrap® 96: a new solid-state platform for high-throughput Chromatin Immunoprecipitation (ChIP)'.

From Chromatrap® - Porvair Sciences Ltd 24 Sep 2014

DNA sequencing may lead to greater care for patients with ventilator-associated pneumonia

A patient survives life-threatening trauma, is intubated in the intensive care unit (ICU) to support his or her affected vital functions, starts to recover, and then develops pneumonia.

23 Sep 2014

GenoSpace awarded NIH grant to enable enhanced data access, cohort construction for biorepositories

GenoSpace, a precision medicine software company that has developed a comprehensive suite of tools to enable the broad use of genomic data in research and clinical care, today announced that it has been awarded Phase I of a Fast Track Small Business Innovation Research Grant from the National Institutes of Health to enable enhanced data access and cohort construction for biorepositories.

23 Sep 2014

Precision Medicine News and Research

Patient's gene profile influences effects of statins

InSilico Medicine, CCARL collaborate to improve personalized medicine projects in multiple sclerosis

Genome Canada awards $6M grant to CAMH and Assurex Health

Researchers identify novel method to develop personalized vaccines for ovarian cancer

University of Pittsburgh awarded NIH grant to lead Big Data to Knowledge Center of Excellence

GenomOncology, med fusion partner to optimize treatment strategies for tumor

MyCartis announces launch of digital multiplex biomarker analysis platform

U-M scientists launch $11.5 million effort to better understand cause of Parkinson's disease

CNIO researchers discover new specific marker for cancer stem cells

Luminex gets FDA approval to add three new targets to xTAG Gastrointestinal Pathogen Panel

Aptose joins Beat AML research collaboration

Early detection of cancers on the horizon with supersensitive nanodevice

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Cedars-Sinai to participate in a consortium studying motor neuron disorders

Eutropics inks NCI contract to develop Praedicare Dx platform technology for AML treatments

AIT, BioVendor and SCIENION partner to develop in-vitro diagnostic test for colon cancer

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

High-throughput ChIP analysis platform introduced in new technical article

DNA sequencing may lead to greater care for patients with ventilator-associated pneumonia

GenoSpace awarded NIH grant to enable enhanced data access, cohort construction for biorepositories

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News